Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 2,031,197 shares, a drop of 14.8% from the February 12th total of 2,383,895 shares. Based on an average daily volume of 307,757 shares, the short-interest ratio is presently 6.6 days. Currently, 8.6% of the shares of the company are sold short. Currently, 8.6% of the shares of the company are sold short. Based on an average daily volume of 307,757 shares, the short-interest ratio is presently 6.6 days.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Financial Management Professionals Inc. purchased a new position in shares of Keros Therapeutics during the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd raised its position in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in Keros Therapeutics during the third quarter valued at $47,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Keros Therapeutics in the third quarter valued at about $103,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Stock Up 0.3%

KROS stock opened at $11.02 on Monday. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $22.55. The firm has a market cap of $217.31 million, a P/E ratio of 6.05 and a beta of 0.87. The company’s 50-day simple moving average is $16.53 and its 200-day simple moving average is $16.93.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The business had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. Keros Therapeutics’s revenue for the quarter was down 87.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.14) EPS. On average, analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of recent research reports. Wells Fargo & Company reduced their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Bank of America upped their price objective on Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Finally, Zacks Research lowered shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $21.86.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.